✦ LIBER ✦

Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial

✍ Scribed by Preeta Tyagi; Axel Grothey

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III Trial of FOLFOX plus Bevacizum

✍ Jane D. Robertson; Nick A. Botwood; Mace L. Rothenberg; Hans-Joachim Schmoll 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 77 KB

Surgery with curative-intent in patients

✍ Okines, A; Puerto, O del; Cunningham, D; Chau, I; Van Cutsem, E; Saltz, L; Cassi 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 162 KB

6010 A three-arm phase III randomized tr

✍ Hoff, P.; Clarke, S.; Cunningham, D.; Van Cutsem, E.; Moore, M.; Schmoll, H.J.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

PCN87 PHARMACOECONOMIC ANALYSIS OF DIREC

✍ A Tikhomirova; A Kulikov; R Yagudina 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

A phase I trial of vandetanib combined w

✍ Elwyn C. Cabebe, George A. Fisher, Branimir I. Sikic 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 112 KB

A Phase III Randomized, Open-Label, Cont

✍ Zev Wainberg; J. Randolph Hecht 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 90 KB